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Abstract
Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating
research. This research is dominated primarily by issues about the nature and design of current and future
clinical trials. Stakeholder engagement for HIV cure remains in its early stages. Our analysis examines timing
and mechanisms of historical stakeholder engagement in other HIV research areas for HIV-uninfected indi-
viduals [vaccine development and pre-exposure prophylaxis (PrEP)], and HIV-infected individuals (treatment
as prevention, prevention of mother-to-child transmission, and treatment of acute HIV infection) and articulate
a plan for HIV cure stakeholder engagement. The experience from HIV vaccine development shows that early
engagement of stakeholders helped manage expectations, mitigating the failure of several vaccine trials, while
paving the way for subsequent trials. The relatively late engagement of HIV stakeholders in PrEP research may
partly explain some of the implementation challenges. The treatment-related stakeholder engagement was
strong and community-led from the onset and helped translation from research to implementation. We outline
five steps to initiate and sustain stakeholder engagement in HIV cure research and conclude that stakeholder
engagement represents a key investment in which stakeholders mutually agree to share knowledge, benefits, and
risk of failure. Effective stakeholder engagement prevents misconceptions. As HIV cure research advances from
early trials involving subjects with generally favorable prognosis to studies involving greater risk and uncer-
tainty, success may depend on early and deliberate engagement of stakeholders.
Introduction
Several reports of an increasing understanding ofHIV virology and immunology have energized the global
scientific community to develop an HIV cure. The first case, a
Berlin patient,1 is an HIV-infected individual who underwent
treatment for acute myeloid leukemia that included inten-
sive preconditioning chemotherapy and total body irradia-
tion, followed by stem cell transplantation with HIV-resistant
(CCR5-positive) cells. HIV could not be detected in the blood
for over 6 years.1,2
The second case, a Mississippi infant,3 initiated antiviral
treatment (ART) at 31 h of life for a period of 18 months,
and subsequently had undetectable plasma viral load for
27 months without ART.34 Two Boston patients, unlike the
Berlin patient, received CCR5-negative cells during stem cell
transplantation for cancer. The preconditioning treatment for
cancer reduced the frequencies of HIV-infected cells and
prolonged the time to plasma viral load rebound.5 The VIS-
CONTI cohort includes 14 patients in France who were treated
during acute HIV infection and subsequently maintained viral
suppression in the absence of ART for more than 5 years.6
Ongoing research is dominated primarily by concerns re-
garding the conduct and progress of the current trials aiming
at durable drug-free viral suppression (functional cure) or
true eradication of HIV (sterilizing cure).7 As of April 2014,
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54 HIV-cure-related trials were ongoing worldwide, and the
number of studies continues to increase ( Jefferys R. Forum
for Collaborative HIV Research, personal communication,
April 23, 2014). Although a cure seems far in the future, we
hypothesize that early inclusive stakeholder engagement in
HIV cure research is essential.
We define HIV cure research stakeholders as those di-
rectly or indirectly involved in organizing HIV cure research
studies.8 Stakeholders include HIV-infected individuals,
key affected populations, the scientific community, funding
agencies, international agencies, public health and regulatory
authorities, pharmaceutical industries, civil society leaders,
and media whose understanding and support have been di-
verse (Table 1). Stakeholder engagement can shape public
perception, contribute to research understanding, facilitate
volunteer recruitment, and help build multi-sectoral coali-
tions.9 It may also contribute to attenuating the risk of failure
and decrease the likelihood of therapeutic misconception.
Methods
We review historical examples of stakeholder engage-
ment in HIV clinical research. We focus on interventions
targeting HIV-uninfected individuals [HIV vaccine trials,
antiretroviral pre-exposure prophylaxis (PrEP)], and HIV-
infected individuals (treatment as prevention, prevention
of mother-to-child transmission, and treatment of acute in-
fection). These interventions are advanced in clinical de-
velopment, or at varying stages of program implementation.
Our objective is to (1) examine the timing, profile, and mech-
anisms of stakeholder engagement in developing and newly
emerging HIV interventions, (2) analyze examples of stake-
holder engagement, and (3) articulate a framework for stake-
holder engagement specific to HIV cure clinical research.
Results
Stakeholder engagement in HIV prevention research
targeting HIV-uninfected individuals
HIV vaccines
Background. The development of a preventive HIV vac-
cine, while elusive, represents a significant scientific effort to
benefit HIV-uninfected populations.10 HIV vaccine develop-
ment faced several critical issues from the start. These in-
cluded scientific challenges, safety concerns, human rights
issues, and stigma affecting engagement of high-risk popula-
tions, and ethical and legal concerns.11,12 However, lengthy
and costly clinical trials were compounded by early failures,
resulting in disappointment.13 Six HIV vaccine efficacy trials
have been conducted, and five of them have failed to show
efficacy after years of intense preparations.14 RV144 was the
first community-based vaccine trial to demonstrate efficacy
with a 31% reduction in HIV acquisition,15 suggesting that
a preventive vaccine may be achievable.16 However, vaccine
efficacy was insufficient to justify public health deployment.
Stakeholder engagement and progression over time. Early
and diversified stakeholder engagement has been key to ad-
vancing HIV vaccine research since nearly three decades.17
This has been particularly important for the vaccine agenda in
low- and middle-income countries that started with deve-
lopment of National AIDS Vaccine Development Plans by
engaging domestic and international stakeholders.18,19 The
timing of stakeholder engagement, essentially driven by
clinical scientific discovery, has from inception remained a
continuum across stakeholders. A regular update of stake-
holders about the global picture (‘‘where do I fit and why?’’)
has become as important as the more specific ‘‘how and
when’’ aspects of HIV vaccine development.
Unlike the first HIV vaccine trials in resource-limited
countries,13 the implementation of new efficacy trials is now
under close scrutiny by communities, scientific and regula-
tory authorities, and funding agencies.20 The factors that
contributed to this situation are essentially the perception of
the successive failure of efficacy trials and controversy
around the implementation of RV144 and Step trial,21,22 that
new vaccine concepts might not do better or even harm,23 the
limited funding, and in some regions, the limited access to
high-risk populations in the midst of other prevention trials.
Moreover, early planning for access deals with manufactur-
ing of the potential vaccine and commitment of manufac-
turers to guarantee supply, ownership of intellectual property,
and cost-benefit of deployment of partially efficacious vac-
cines.24–26 Modeling the potential impact and the cost-
benefits 27–30 of an HIV vaccine amid combination prevention
modalities required in-depth discussions with various stake-
holders.10,31–33 For example, would an HIV vaccine still be of
public health benefit and cost-effective if HIV cure along
with PrEP and treatment as prevention in men who have sex
with men (MSM) and transgender individuals are deployed?
One could speculate that a vaccine may be efficacious but of
little to no cost-benefit depending on the efficacy rate and the
dynamics of the epidemic.
While heterosexual transmission prevails in Africa, MSM
and transgender women, sex work, and people who inject
drugs (PWID) drive the epidemic in Asia.34 HIV incidence in
Asian heterosexual populations is now too low to justify large
and costly efficacy trials similar to RV144. Efficacy trials in
Asia will likely target MSM and transgender women.35,36
This generates the dilemma of a vaccine proven to be effi-
cacious in a high-risk population and that may or may not be
efficacious in other groups. Here again, a dialogue remains
essential for stakeholders to understand this paradoxical si-
tuation and to analyze the possible public health and regu-
latory implications.
Strengths and weaknesses of stakeholder engagement.
The stakeholder engagement in HIV vaccine research started
early and was broadly inclusive. From inception of research it
facilitated political and ethical approval of clinical trials,
community support, enrollment of participants, and planning
for potential future implementation. Stakeholder engagement
may vary with the governance of the country. The experience
from vaccine research showed that countries with a highly
centralized decision-making process may be more difficult to
convince and engage, in particular when HIV vaccines are/
were proposed to be tested for the first time.
Pre-exposure prophylaxis
Background. Oral PrEP for HIV-uninfected individuals
reduces HIV acquisition in MSM,37 serodiscordant cou-
ples,38 and PWID.37, 39 PrEP showed conflicting results in
heterosexual acquisition of HIV in women.40,41 A recent
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meta-analysis of seven PrEP randomized controlled trials
demonstrated an overall risk reduction of 47% confirming
previous findings.42,43 PrEP research is evolving with 17
ongoing studies44 assessing the efficacy of PrEP in new
populations (adolescents at high risk and transgender), de-
velopment of new drug delivery systems, formulations with
longer half-life, and open-label extension of prior efficacy
trials.45 The approval of Truvada (oral tenofovir disoproxyl
fumarate and emtricitabine) for PrEP by the US Food and
Drug Administration (FDA) in 201246 and the release of
guidelines by WHO47–49 and CDC50,51 recommending PrEP
for certain populations represented a significant biomedical
Table 1. Stakeholders Domains and Rationale of Engagement in HIV Vaccine Development
Stakeholder Examples (nonexhaustive) Domains and rationale of engagement
International
agencies
WHO, UNAIDS, World Bank Catalyzer for National HIV Vaccine Development
Plan, HIV Vaccine Advisory Committee, advocacy,
policy and guidelines, monitoring & evaluation,
expert review committees and working groups, ad
hoc review of clinical trial proposals, normative
communication of scientific results, continuum of
engagement across stakeholders, health economy




Academic institutions (US NIH VRC,
HIV Vaccine Working Group and the
AIDS Research Advisory Committee,
BMGF, MHRP, CDC, HVTN, UK
MRC), Global HIV Vaccine Enterprise,
research agencies (IAVI, KAVI,
SAAVI, EuroVacc, ANRS, ICMR),
African AIDS Vaccine Programme,
Institutional scientific advisory
committees
Drive the global scientific agenda and tailor the agenda
to country and/or regional needs. Implement clinical
trials, generate and communicate results
Monitor the HIV epidemic and contribute to the
establishment of national guidelines and National
HIV Vaccine Development Plans





US NIH, USAID, BGMF, US Army,
ANRS, AFPPD, European Community,
Governments, private donors
Key stakeholders whose contribution is essential to the





US NIH, Ministry of (Public) Health,
country-specific regulatory authorities
(e.g., US FDA, EMA, Thai FDA, South
African Health Products Regulatory
Authority, NACO, China FDA)
Tailor the scientific agenda to the country-specific HIV
epidemic and community needs. Ensure that the
products tested comply with national regulations.
Responsible for national policy and deployment
strategies
Are in constant dialogue with the scientific community
and other stakeholders for discussions and
requirements on licensure and access
Civil society People living with HIV (PLHIV), key
populations, advocacy groups (AVAC,
IAVI), CAB, NGO, Ethics Committees,
Institutional Review Boards, Legal
groups
Contribute to a broad range of activities from
advocacy, human rights, ethics and legal
considerations, and represent the key interface with
the scientific community
Convey expectations and concerns from the public
targeted for HIV vaccine trials and deployment
Key stakeholders for the recruitment and follow-up of
volunteers for clinical trials
Pharmaceutical
industry
Sanofi Pasteur, Novartis, Merck,
GlaxoSmithKline, GSID, Biotech
companies, CMOs
Contribute to the design of the scientific agenda,
manufacture and supply products to be tested in
humans and work on access and licensure with
national public health and regulatory authorities
Media Newspapers, TV, radio, internet,
newsletters
Relay general scientific findings to the public and
convey expectations and concerns
Can positively contribute to global, regional and
national HIV vaccine advocacy and conversely
mislead public opinion
ANRS, Agence Nationale de Recherche sur le Sida, France; AVAC, Global Advocacy for HIV prevention; BMGF, Bill & Melinda Gates
Foundation; CAB, Community Advisory Board; CDC, Centers for Disease Control and Prevention, USA; China FDA, Food and Drug
Administration; CMOs, Contract Manufacturing Organizations; EMA, European Medicines Agency; FDA, US Food and Drug
Administration; GSID, Global Solutions for Infectious Diseases; HVTN, HIV Vaccine Trials Network; IAVI, International AIDS Vaccine
Initiative; ICMR, Indian Council of Medical Research, India; KAVI, Kenya AIDS Vaccine Initiative; MHRP, US Military HIV Research
Program; NACO, National AIDS Control Organisation, India; NGO, Nongovernmental organization; NIH VRC, National Institutes of
Health, Vaccine Research Centre; SAAVI, South Africa AIDS Vaccine Initiative; UK MRC, United Kingdom Medical Research Council.
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breakthrough in HIV prevention. Yet, implementation of
PrEP outside of clinical trials has been slow and faces sub-
stantial scepticism.52
Evolution of stakeholder engagement. Early PrEP trials in
Cambodia, Cameroon, Malawi, and three West African sites
failed to launch or were stopped prematurely due to ethical,
political, and logistical concerns raised by civil society
leaders in 2004.53–55 The start of the Bangkok Tenofovir
PrEP study was delayed for several years.56 Activists ex-
pressed concerns about side effects of antiretrovirals in HIV-
uninfected individuals, and the absence of some prevention
modalities and treatment services. Lack of insurance cover-
age for seroconverters and adverse events related to the trial
drugs were among the issues raised. Most importantly, activ-
ists criticized the lack of engagement of affected communities
in the trial design.57 Broader stakeholder engagement started
in 2005, and only in 2008 WHO, UNAIDS, the Forum for
Collaborative HIV Research, and the Global Advocacy of HIV
Prevention (AVAC) engaged in preparing for potential PrEP
implementation with the support of the DAIDS, US NIH, and
the BMGF.58–60 Debate about the potential implementation of
PrEP in resource-limited settings started.61–64
Early modeling studies postulated that PrEP could poten-
tially have a positive impact as part of combination preven-
tion.65,66 By that time, research efforts had already advanced
considerably.61,67,68 Subsequent trials were more successful
in involving the community, government, and strong over-
sight of study operations.59 Illustrating that civil society can
influence the implementation of scientific findings, a 2011
letter of US activists to the US Food and Drug Administration
was issued to review the PrEP tenofovir/emtricitabine daily
regimen.69
The principle of vaccines is well known to the public and
generally well accepted, while it is entirely different for
PrEP. Substantial knowledge gaps still exist to determine the
acceptability of PrEP among affected communities and how
to deliver PrEP to diverse populations in different settings.61
Data on acceptability of PrEP are not conclusive. Among
MSM and transgender individuals in Northern Thailand and
Bangkok, PrEP uptake could be considerable despite multi-
ple challenges related to HIV testing requirements.70 How-
ever, the high cost of drugs remains a significant barrier.71
Pilot demonstration projects plan to address these challenges
on smaller, more controllable scale.59
Communication about PrEP remains challenging and re-
quires a clear message on how PrEP complements—and does
not compete with—existing prevention messages and re-
source for treatment. Because PrEP is administered in heal-
thy, HIV-uninfected individuals, many potential users
continue to express concerns about drug side effects, where
even mild effects may compromise adherence and hence fail
to work.72 PrEP is still considered an individual prevention
intervention for HIV-uninfected individuals at a time where
governments struggle to sustain funding for HIV treatment
programmes,69 although the still high HIV incidence among
MSM in view of failure of other prevention technologies is an
argument to include PrEP for HIV prevention for this par-
ticular group.73–75
Strengths and weaknesses of stakeholder engagement.
Insufficient stakeholder engagement during PrEP clinical
trials may only partially explain current implementation
challenges. The early termination or delayed implementation
of some PrEP trials suggests that communication between
stakeholders and key populations was inadequate. Earlier
engagement of key populations, policy makers, and planners
could have resulted in better understanding of the social
meaning, ethical considerations, and economic consequences
of PrEP research and anticipated these challenges for future
implementation. International agencies have provided de-
terminant leadership in helping to engage the broader com-
munity in the ethical conduct of ongoing PrEP trials and
planning for implementation.
Stakeholder engagement in HIV prevention research
targeting HIV-infected individuals
Treatment as prevention (TasP)
Background. The introduction of antiretroviral therapy
(ART) and WHO’s public health approach to HIV treatment
in resource-limited settings have changed the course of the
HIV epidemic.76,77 The results of HPTN 052 provided firm
evidence that earlier ART reduces the risk of heterosexual
HIV transmission confirming results from observational and
ecological studies.78–84 Responding to this scientific break-
through, the 2013 WHO guidelines were revised to recom-
mend that all adults and adolescents should initiate treatment
at a CD4 £ 500 cells/uL.48 The WHO guideline development
process itself is firmly based on inclusive stakeholder en-
gagement and management of conflict of interest.85,86
Stakeholder engagement and progression over time. The
HPTN 052 study team went through considerable challenges
since inception of the trial.87 Initial discussions on the study
design started in 1993, but the study was only approved by
concerned institutional review boards (IRBs) in 1999 and by
ACTG in 2001. As most of the study sites were in low- and
mid-income countries where access to treatment was not
uniformly available, obtaining ART for the study took an-
other 4 years (2002–2005). The HPTN pilot phase from
2005–2007 finally led to study enrolment which commenced
only in 2007 and took another 4 years. The delay was due to
the array of ethical challenges that jeopardized both, the
planning and implementation of the trial: People living with
HIV demanding access to treatment,88,89 the changing
threshold of WHO guidelines, the debate about HIV preven-
tion commodities, and the belief of some stakeholders that the
biological plausibility of TasP did not warrant a randomized
clinical trial. The study team responded to multiple stake-
holder requests using existing communication channels and
platforms. Today, community advisory boards representing
people living with HIV and key populations remain the driving
force to address treatment access-related matters and their
engagement is more and more driven by science.90
The findings of HPTN 052 created hope that elimination of
new HIV infections was possible and had a galvanizing effect
on health authorities, global convenors of stakeholders
around HIV policies and guidelines such as PEPFAR and
WHO.91 In 2012, PEPFAR convened stakeholders at its
Scientific Advisory Board. WHO engaged stakeholders very
early in the debate through publishing projections for the
potential elimination of HIV,92 coordinating stakeholder
consultations on the strategic use of antiretrovirals,93 and
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recommending TasP for serodiscordant couples and pregnant
women in its guidelines.48,94
Strengths and weaknesses of stakeholder engagement.
Stakeholder engagement for treatment dates back to the
Denver Principles and called for action by treatment activists.
The communication between study teams and stakeholders
made use of established channels and platforms for HIV
treatment. It would not have been without inclusive stakeholder
consultations that the results of HPTN 052 had prompted Health
Authorities to consider earlier initiation of ART.95–97
Prevention of mother-to-child transmission of HIV
Background. Transmission of HIV from mother-to-child is
the main source of HIV infection in children.98 Efficacious
antiretroviral regimens to prevent mother-to-child transmis-
sion of HIV (PMTCT), available since the mid-nineties,98–100
are considered cost-effective.101 However the history of
PMTCT of HIV in resource-limited countries faced a number
of technical issues over the past 15 years, ranging from deter-
mining optimal HIV testing and counseling strategies, choice of
infant feeding practices, to the most effective and appropriate
antiretroviral interventions.102 Progress has been amazingly
slow reflecting implementation challenges.102 The 2013 WHO
guidelines now recommend that all pregnant HIV-infected
women should receive triple antiretroviral therapy at least for
the duration of transmission risk (Option B) and then either
carry on lifelong treatment irrespective of CD4 count (Option
B + ), or for those who are eligible to be given life-long.48 These
guidelines also recommend early infant diagnosis and imme-
diate treatment for children less than 5 years old.
Stakeholder engagement and progression over time. The
conduct of efficacy trials of short-course PMTCT regimens in
resource limited settings100,103 led to vivid debate about the
ethical conduct of trials in such settings among a wide range
of stakeholders.104,105 Fortunately, short-course regimens
were proven efficacious, resulting in a paradigm shift from
administering ARVs in specialized clinical services to ad-
ministering short-course regimens in government pro-
grammes.106,107 The United Nations Children’s Fund and the
WHO initiated a stakeholder platform named the Interagency
Task Team on the Prevention and Treatment of HIV Infection
in Pregnant Women, Mothers and Children (IATT), which
continuously expanded to include maternal child health
constituencies, mothers living with HIV and their part-
ners.108,109 The IATT helped engage high level policy mak-
ers and champions in PMTCT efforts.110,111 Activities
included, for example, advocacy, scientific dialogue, and
support of pilot projects in resource-limited countries.
Regular stakeholder meetings have taken place until to
date, yet the expansion of PMTCT has not met the initial high
expectations.112,113 Prevailing stigma and discrimination
against HIV and weak maternal child health services ham-
pered the implementation of PMTCT and may have limited
early engagement of mothers living with HIV.114 However
without stakeholder engagement, the transition from design
and conduct of clinical trials to implementation may not have
happened at even slower pace.
The prospect of HIV cure in HIV-infected infants has now
triggered interest in diagnosing babies born to mothers with
HIV early and providing immediate treatment as developed
below. Initial stakeholder consultations for HIV cure and
PMTCT have taken place in Thailand (Developed below) and
South Africa.115
Strength and weaknesses of stakeholder engagement.
Early stakeholder engagement has been key to advancing
both research and implementation for PMTCT. PMTCT is
providing an example how wide stakeholder engagement
continues when moving from research to implementation.116
A weakness of stakeholder engagement in PMTCT was that
civil society leadership comparable for treatment access
campaigns had not happened with the same magnitude and
failed to engage maternal child health stakeholders from
the onset.114
Treatment of acute HIV infection and HIV cure research
Background. The case of the Mississippi baby has raised
hopes that a functional cure can be achieved with early ART
alone.3 This sparked interest in diagnosing HIV during very
early acute infection and administration of immediate ART to
reduce the HIV reservoir as a potential strategy for a func-
tional cure. Thailand is the first Asian country to engage in
such new research. The RV254/SEARCH 010 study con-
ducted in adult volunteers,117 and the HIV-NAT 194 in
children in Thailand118 showed remarkably low reservoir size
following very early ART. Other studies show that control of
viral replication at the time of HIV seroconversion may
curtail cumulative immunological damage119 and preserve
and restore lymph node structure.120,121
Stakeholder engagement and progression over time. We
describe two types of stakeholder engagement in the context
of early treatment of acute HIV infection in the context of
cure research in Thailand, one in adults and the other in
children.
Considerations for the adult population. The RV254/
SEARCH 010 study began in 2009 as a pilot cohort to un-
derstand the early immunologic and virologic events in HIV
proposed to be germane for preventive HIV vaccine devel-
opment.122 ART was offered and fortunately almost every-
one in RV254 chose treatment, allowing for assessment of its
impact on reservoir size. Over the past 5 years, the RV254/
SEARCH 010 study has evolved to become a cohort of early
treated candidates for cure research.123 A host of studies are
being developed for this Thai cohort, all of which will require
analytic treatment interruption (ATI), and some will involve
investigational drug or immune-based therapy.
Experience in Thai HIV cure research was one of gradual
stakeholder involvement. First contact was limited between
key researchers from an existing scientific collaboration be-
tween the US Military HIV Research Program and the Thai
Red Cross AIDS Research Center to plan and develop the
research proposal. The US partner engaged other US scien-
tists, whereas the Thai researchers engaged local specialists
and laboratory scientists, as well as the Thai government and
industry for antiretrovirals. The community advisory board
(CAB) helped with counseling of trial participants about
purpose and results of acute HIV infection screening and the
options for immediate ART to potential trial participants,
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both of which were different from standard practices in
Thailand. Initially few acute infection cases were identified
due mainly to misconception of a long window period,
leading to the Thai Red Cross launching a campaign to pro-
mote early testing using nucleic acid testing (NAT) that was
supported by Thai celebrities and government, nongovern-
ment organizations, and civil society. This, together with
starting the HIV ’edutainment’*website for MSM ‘Adam’s
Love,’ resulted in significant rise in identification of persons
with acute HIV infection.124,125 There are ongoing efforts by
the Thai research community to effectively communicate the
objectives, risks, and benefits of cure-related studies to re-
search participants and other stakeholders.
Specific considerations for the pediatric population. Chil-
dren are a vulnerable population, and cure trials using in-
vestigational drugs will likely be conducted in children after
some demonstrable favorable safety and efficacy profile in
adults. A core group of academics who are key opinion
leaders in the pediatric HIV field in Thailand coalesced to
engage other stakeholders with a goal to improve uptake of
early diagnosis and ART in HIV-infected children in prepa-
ration of the research proposal for an HIV cure study in HIV-
exposed newborns (NIAID 1R01AI114236-01). The com-
munication mechanisms established for PMTCT and pediatric
HIV were used to link the trial to the national PMTCT pro-
gram. The group approached and received support from the
Ministry of Public Health, which convened an advisory board
to prioritize this as a national agenda. Working group meet-
ings with Ministry’s directors and project managers, pediatric
infectious diseases specialists, health care personnel, and
civil society were conducted to discuss modifications of
systems and mobilization of resources to reach the approxi-
mately 100 infants born with HIV in Thailand each year.
Strength and weaknesses of stakeholder engagement. The
example from Thailand shows the overlap between research
and stakeholder engagement for HIV vaccine development,
ART, PMTCT and HIV cure research and that HIV cure
research can benefit from existing platforms. To gain a higher
public health impact, involvement of policy makers, key
opinion leaders and civil societies from the inception phase is
important as demonstrated in the context of cure research and
treatment guideline revision in Thailand to advocate for
earlier ART. Engagement of the media, government, and
civil societies was key in mitigating misconceptions regard-
ing HIV cure in Thailand. For example, when the Mississippi
baby case became public news, sensationalized and incorrect
reporting said that ‘‘Thai patients’’ who were treated early
had also been cured.
Discussion
Call for inclusive and broad stakeholder
engagement in HIV cure research
More individual risks than benefits are raised for the many
interventions currently being proposed for cure.126,127 En-
gagement of potential trial participants about their expecta-
tions and the associated risks and benefits will be critical. As
disappointing findings emerge from several key studies, such
as failure to maintain suppressed viremia post ATI in the
bone marrow transplanted patients from Boston,128 or failure
to reduce the reservoir size using histone deacetylase inhib-
itors (HDACi),126 the prospect for success may seem far.
Therefore, stakeholder engagement is particularly impor-
tant in HIV cure research and should be based on the prin-
ciples laid out by AIDS activists in 1983. The Denver
Principles, which called for respect and involvement of civil
society at every level of decision-making, apply to HIV cure.
This should start from planning of type of clinical trials,
continue during study, and dissemination of results.129 The
direct involvement of AIDS activists in every aspect of a
research agenda led to mechanisms such as the Community
Constituency Group of the AIDS Clinical Trials Group and
Table 2. Stakeholder Engagement
Stages of
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local advisory boards.130 However, stakeholder engagement
in HIV cure research does not equal setting up a CAB. The
limitations of CABs have been described elsewhere.131,132
Although definitely important, they may not be sufficient as
in the case of early HIV prevention trials.57
Most HIV cure researchers would probably respond to this
article by saying that their CAB is sufficient, but we are
arguing for moving beyond based on the historic lessons
learnt from other HIV interventions. The scientific commu-
nity can request other entities to take charge of convening
stakeholders, which is already happening today through the
HIV cure working groups convened by the Internal AIDS
Society, the Forum for HIV Collaborative Research, and the
Social and Ethical Working Group on HIV Cure.9
Stakeholder engagement advanced the research agenda for
treatment and was clearly a major factor in the introduction of
treatment for HIV prevention as global public health policies
today.78,88,91 The failure to engage civil society beyond the
enrollment of trial participants clearly backfired in the case of
PrEP.53–55,57 Being inclusive from the early onset of planning
research should already take into account potential public
health interest and cost issues in HIV cure. Early discussion
of risks and benefits of HIV cure amid combination of other
prevention and treatment modalities are needed.33 Having an
understanding on how different stakeholders would rank HIV
cure along with other existing prevention interventions such
as PrEP and TasP could be an important tool for HIV cure
stakeholder mapping and engagement. This review also
shows the considerable challenges of HIV research ethics.
HIV cure and related social research around stakeholder
engagement could inform evolving research ethics.133
We propose that early and inclusive stakeholder engage-
ment (Table 1) should also apply for HIV cure research. We
propose five steps for inclusive stakeholder engagement from
the early planning of studies and inception of clinical trials
(Table 2).We also acknowledge that managing conflict of
interest in stakeholder engagement is important. For exam-
ple, to what extent do Government agendas determine
engagement in research and how would they affect cure re-
search? To what extent do personal and corporate interests
affect cure research and drive the formulation of research
agenda?
Since stakeholders from different prevention and treatment
areas do vastly overlap, a more comprehensive approach of
combining stakeholder engagement across different HIV
research areas and in support to future implementation should
be envisaged. This may prevent compartmentalizing the HIV
research agenda and save resources. Stakeholder engagement
may be easier as long as science and clinical trials are the
main subject of discussion, but is much more difficult when
cost-benefits, intellectual property, public health budget, and
deployment strategies are envisaged.
While the prospect of HIV cure is currently more of ‘in-
dividual’ benefit and perhaps possible in only a subset of
HIV-infected individuals, there is cautious optimism that
knowledge gained from these selected individuals could lead
to better interventions for the general HIV-infected popula-
tion. The recent history of HIV interventions suggest that a
concerted effort for transparent and multi-directional en-
gagement among stakeholders may help address expecta-
tions, answer questions, clarify misconceptions, manage
failure, and prepare for success in a timely manner. Stake-
holder engagement is a necessary component of HIV cure
research. As HIV cure research advances from early trials
involving subjects with generally favorable prognosis to
studies involving greater risk and uncertainty, success will
depend on early and deliberate engagement of stakeholders.
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